1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Concordia in clear on three products in UK

 
• By Aidan Fry

Concordia International no longer faces a UK probe into “alleged anti-competitive agreements and/or concerted practices” for three of the firm’s products – trazodone, nefopam and dicycloverine – after the country’s Competition and Markets Authority (CMA) closed an investigation on “administrative priority grounds”.

Concordia International no longer faces a UK probe into “alleged anti-competitive agreements and/or concerted practices” for three of the firm’s products – trazodone, nefopam and dicycloverine – after the country’s Competition and Markets Authority (CMA) closed an investigation on “administrative priority grounds”.

“This decision does not prevent the CMA from opening a new investigation into these products in the future,” Concordia acknowledged,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By Dean Rudge

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.

Lupin Launches Generic Version Of Lilly’s Discontinued Glucagon In The US

 
• By Urtė Fultinavičiūtė

Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.

‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs

 
• By Urtė Fultinavičiūtė

As Amneal reports another solid quarterly performance, with refinanced debt and adjusted financial guidance for the year, will Trump’s “chaotic” tariffs shake it all up?

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By Dave Wallace

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

More from Business

Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage

 
• By Dean Rudge

Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.

‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs

 
• By Urtė Fultinavičiūtė

As Amneal reports another solid quarterly performance, with refinanced debt and adjusted financial guidance for the year, will Trump’s “chaotic” tariffs shake it all up?

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.